Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers

NEW YORK, August 21, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.

--
Mallinckrodt PLC Research Reports
On August 14, 2014, Mallinckrodt PLC (Mallinckrodt) announced that it has completed the acquisition of Questcor Pharmaceuticals, Inc. (Questcor) for approximately $5.8 billion in a cash and stock transaction. The Company informed that the merger was approved by the shareholders of both the companies. According to the terms of the agreement, Questcor shareholders will receive $30.00 in cash and 0.897 of a Mallinckrodt ordinary share for each Questcor share. The Company further informed that the acquisition is expected to be immediately accretive to Mallinckrodt's FY 2014 adjusted diluted EPS and significantly accretive to its adjusted diluted EPS in FY 2015. Mark Trudeau, President and CEO, Mallinckrodt, said, "We are pleased to complete this transformative transaction and believe it will provide a strong, durable, well-diversified and sustainable platform, capable of generating significant future revenue and earnings growth for Mallinckrodt shareholders." The full research reports on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/MNK/report.pdf

--
Celgene Corporation Research Reports
On August 19, 2014, Celgene Corporation (Celgene) announced the online publication of the results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL), ahead of print in the Journal of Clinical Oncology. The Company stated that in a phase II, open label, single arm study, by Dr. Grzegorz Nowakowski of the Mayo Clinic, the overall response (OR) rate was 98% (59/60) and complete response (CR) rate was 80% (48/60). Dr. Nowakowski commented, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL." The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/CELG/report.pdf

--
Actavis plc Research Reports
On August 19, 2014, Actavis plc (Actavis) announced the positive topline results from RECLAIM-1 and -2, pivotal Phase III studies which evaluated the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients suffering from complicated intra-abdominal infections. The Company informed that in the RECLAIM-1 and RECLAIM-2 Phase III studies, ceftazidime-avibactam met the objective of statistical non-inferiority compared to meropenem. The primary endpoint was a clinical cure rate 28 to 35 days after randomization (the Test of Cure visit). Ceftazidime-avibactam was also effective in treating cIAI patients infected with ceftazidime-resistant bacteria. Commenting on the results, David Nicholson,PhD, Senior Vice President, Actavis Global Brands R&D, "We are very pleased by these results, which support the potential of ceftazidime-avibactam as a new treatment option for patients with these serious and life-threatening intra-abdominal infections." The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/ACT/report.pdf

--
UnitedHealth Group Inc. Research Reports
On August 13, 2014, UnitedHealth Group Inc. (UnitedHealth) announced that the Company's Board of Directors authorized a Q3 2014 dividend of c.$0.38 per share on its common stock on August 12, 2014. The authorized dividend will be paid on September 23, 2014 to shareholders of record as on September 12, 2014. The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/UNH/report.pdf

--
Bristol-Myers Squibb Co. Research Reports
On August 18, 2014, Bristol-Myers Squibb Co.'s (Bristol-Myers) stock moved up 0.62% to end the trading session at $49.99, following the S&P 500 that moved up 0.85% over the same trading session. Shares in Bristol-Myers opened the session at $49.94 and fluctuated between $49.77 and $50.13. The stock has a 52-week high of $57.49 and a 52-week low of $41.11. Over the past one month, the stock has returned 1.77%, outperforming the S&P 500 that lost 0.33% over the same time period. The full research reports on Bristol-Myers are available to download free of charge at:

http://www.analystsreview.com/Aug-21-2014/BMY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED